Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Apr;73(8):989–994. doi: 10.1038/bjc.1996.193

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.

F D Goebel 1, D Goldstein 1, M Goos 1, H Jablonowski 1, J S Stewart 1
PMCID: PMC2075823  PMID: 8611437

Abstract

The utility of current chemotherapeutic regimens in the treatment of AIDS-related Kaposi's sarcoma (AIDS-KS) is often compromised by both limited efficacy and substantial toxicity. Pegylated (Stealth) liposomal doxorubicin hydrochloride (SL-DOX) has been demonstrated specifically to deliver high concentrations of doxorubicin to Kaposi's sarcoma (KS) lesions. This phase II study was performed to evaluate the efficacy and safety of SL-DOX in the treatment of moderate to severe AIDS-KS. Patients were treated biweekly with 10, 20, or 40 mg m-2 SL-DOX. Tumour response was assessed according to AIDS Clinical Trials Groups (ACTG) criteria before each cycle. Best response was determined for 238 patients and was achieved after a mean of 2.3 cycles (range 1-20). Fifteen patients (6.3%) had a complete response to SL-DOX, 177 (74.4%) had a partial response, 44 (18.5%) had stable disease and two (0.8%) had disease progression. SL-DOX was well tolerated: ten patients discontinued therapy because of adverse events, in four cases because of neutropenia. Grade 3 or 4 neutropenia occurred after 281 of 2023 cycles (13.9%) but involved 137 of 240 patients (57.1%) for whom data were available. SL-DOX has substantial activity in AIDS-KS. Best response is typically seen after fewer than three cycles of chemotherapy and in some cases may be prolonged. The most important adverse event is neutropenia, which occurs after a minority of cycles but which may occur in over half of all patients.

Full text

PDF
989

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Des Jarlais D. C., Stoneburner R., Thomas P., Friedman S. R. Declines in proportion of Kaposi's sarcoma among cases of AIDS in multiple risk groups in New York City. Lancet. 1987 Oct 31;2(8566):1024–1025. doi: 10.1016/s0140-6736(87)92586-4. [DOI] [PubMed] [Google Scholar]
  2. Fischl M. A., Dickinson G. M., La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988 Feb 26;259(8):1185–1189. doi: 10.1001/jama.259.8.1185. [DOI] [PubMed] [Google Scholar]
  3. Fischl M. A., Krown S. E., O'Boyle K. P., Mitsuyasu R., Miles S., Wernz J. C., Volberding P. A., Kahn J., Groopman J. E., Feinberg J. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1993 Mar;6(3):259–264. [PubMed] [Google Scholar]
  4. Freedberg K. A., Tosteson A. N., Cohen C. J., Cotton D. J. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991;4(5):521–531. [PubMed] [Google Scholar]
  5. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994 Feb 15;54(4):987–992. [PubMed] [Google Scholar]
  6. Gallant J. E., Moore R. D., Richman D. D., Keruly J., Chaisson R. E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992 Dec;166(6):1223–1227. doi: 10.1093/infdis/166.6.1223. [DOI] [PubMed] [Google Scholar]
  7. Gelmann E. P., Longo D., Lane H. C., Fauci A. S., Masur H., Wesley M., Preble O. T., Jacob J., Steis R. Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. Am J Med. 1987 Mar;82(3):456–462. doi: 10.1016/0002-9343(87)90445-1. [DOI] [PubMed] [Google Scholar]
  8. Gill P. S., Rarick M. U., Espina B., Loureiro C., Bernstein-Singer M., Akil B., Levine A. M. Advanced acquired immune deficiency syndrome-related Kaposi's sarcoma. Results of pilot studies using combination chemotherapy. Cancer. 1990 Mar 1;65(5):1074–1078. doi: 10.1002/1097-0142(19900301)65:5<1074::aid-cncr2820650505>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  9. Gill P. S., Rarick M., McCutchan J. A., Slater L., Parker B., Muchmore E., Bernstein-Singer M., Akil B., Espina B. M., Krailo M. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med. 1991 Apr;90(4):427–433. [PubMed] [Google Scholar]
  10. Gill P., Rarick M., Bernstein-Singer M., Harb M., Espina B. M., Shaw V., Levine A. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol. 1990 Aug;13(4):315–319. doi: 10.1097/00000421-199008000-00010. [DOI] [PubMed] [Google Scholar]
  11. Gordon K. B., Tajuddin A., Guitart J., Kuzel T. M., Eramo L. R., VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995 Apr 15;75(8):2169–2173. doi: 10.1002/1097-0142(19950415)75:8<2169::aid-cncr2820750822>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  12. Grody W. W., Cheng L., Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol. 1990 Jul 15;66(2):203–206. doi: 10.1016/0002-9149(90)90589-s. [DOI] [PubMed] [Google Scholar]
  13. Hengge U. R., Brockmeyer N. H., Rasshofer R., Goos M. Fatal hepatic failure with liposomal doxorubicin. Lancet. 1993 Feb 6;341(8841):383–384. doi: 10.1016/0140-6736(93)90198-p. [DOI] [PubMed] [Google Scholar]
  14. Hirschel B., Lazzarin A., Chopard P., Opravil M., Furrer H. J., Rüttimann S., Vernazza P., Chave J. P., Ancarani F., Gabriel V. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med. 1991 Apr 18;324(16):1079–1083. doi: 10.1056/NEJM199104183241602. [DOI] [PubMed] [Google Scholar]
  15. Kaplan L., Abrams D., Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep. 1986 Sep;70(9):1121–1122. [PubMed] [Google Scholar]
  16. Krown S. E., Metroka C., Wernz J. C. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989 Sep;7(9):1201–1207. doi: 10.1200/JCO.1989.7.9.1201. [DOI] [PubMed] [Google Scholar]
  17. Lane H. C., Kovacs J. A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J. A., Baseler M., Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218–1222. doi: 10.1016/s0140-6736(88)90811-2. [DOI] [PubMed] [Google Scholar]
  18. Lassoued K., Clauvel J. P., Katlama C., Janier M., Picard C., Matheron S. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer. 1990 Nov 1;66(9):1869–1872. doi: 10.1002/1097-0142(19901101)66:9<1869::aid-cncr2820660903>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  19. Laubenstein L. J., Krigel R. L., Odajnyk C. M., Hymes K. B., Friedman-Kien A., Wernz J. C., Muggia F. M. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol. 1984 Oct;2(10):1115–1120. doi: 10.1200/JCO.1984.2.10.1115. [DOI] [PubMed] [Google Scholar]
  20. Lokich J. J., Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984 Dec;101(6):798–799. doi: 10.7326/0003-4819-101-6-798. [DOI] [PubMed] [Google Scholar]
  21. Masur H., Ognibene F. P., Yarchoan R., Shelhamer J. H., Baird B. F., Travis W., Suffredini A. F., Deyton L., Kovacs J. A., Falloon J. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Aug 1;111(3):223–231. doi: 10.7326/0003-4819-111-3-223. [DOI] [PubMed] [Google Scholar]
  22. Mintzer D. M., Real F. X., Jovino L., Krown S. E. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Feb;102(2):200–202. doi: 10.7326/0003-4819-102-2-200. [DOI] [PubMed] [Google Scholar]
  23. Papahadjopoulos D., Allen T. M., Gabizon A., Mayhew E., Matthay K., Huang S. K., Lee K. D., Woodle M. C., Lasic D. D., Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460–11464. doi: 10.1073/pnas.88.24.11460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Payne T. H., Cohn D. L., Davidson A. J., Henry T. D., Schaefer J. W., Gabow P. A. Marked elevations of serum alkaline phosphatase in patients with AIDS. J Acquir Immune Defic Syndr. 1991;4(3):238–243. [PubMed] [Google Scholar]
  25. Peters B. S., Beck E. J., Coleman D. G., Wadsworth M. J., McGuinness O., Harris J. R., Pinching A. J. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ. 1991 Jan 26;302(6770):203–207. doi: 10.1136/bmj.302.6770.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Presant C. A., Scolaro M., Kennedy P., Blayney D. W., Flanagan B., Lisak J., Presant J. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet. 1993 May 15;341(8855):1242–1243. doi: 10.1016/0140-6736(93)91147-e. [DOI] [PubMed] [Google Scholar]
  27. Rahman A., Treat J., Roh J. K., Potkul L. A., Alvord W. G., Forst D., Woolley P. V. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol. 1990 Jun;8(6):1093–1100. doi: 10.1200/JCO.1990.8.6.1093. [DOI] [PubMed] [Google Scholar]
  28. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F. M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995 Jul;13(7):1777–1785. doi: 10.1200/JCO.1995.13.7.1777. [DOI] [PubMed] [Google Scholar]
  29. Vaage J., Mayhew E., Lasic D., Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer. 1992 Jul 30;51(6):942–948. doi: 10.1002/ijc.2910510618. [DOI] [PubMed] [Google Scholar]
  30. Vogelzang N. J., Ratain M. J. Cancer chemotherapy and skin changes. Ann Intern Med. 1985 Aug;103(2):303–304. doi: 10.7326/0003-4819-103-2-303_3. [DOI] [PubMed] [Google Scholar]
  31. Volberding P. A., Abrams D. I., Conant M., Kaslow K., Vranizan K., Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Sep;103(3):335–338. doi: 10.7326/0003-4819-103-3-335. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES